IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a private biotech company creating novel cellular secretome therapies for age and disease-related immune decline, is delighted to have Professor Irina Conboy on its Scientific Advisory Board. Dr. Conboy is a Professor of Bioengineering at UC Berkeley, investigator at the Quantitative Biology Institute, and Editor in Chief of Rejuvenation Research.

加利福尼亚州欧文（BUSINESS WIRE）-Immunis，Inc。是一家私营生物技术公司，为年龄和疾病相关的免疫衰退创造新的细胞分泌组疗法，很高兴有Irina Conboy教授担任其科学顾问委员会成员。Conboy博士是加州大学伯克利分校生物工程教授，定量生物学研究所研究员，复兴研究主编。

Her groundbreaking studies have unveiled critical paradigms on the effects of age-related and pathological changes on tissue maintenance and repair, setting the stage for novel therapeutic interventions..

她的开创性研究揭示了与年龄相关和病理变化对组织维持和修复的影响的关键范例，为新的治疗干预奠定了基础。。

A Stanford Ph.D. graduate, Dr. Conboy is a renowned secretome researcher that has consistently been at the forefront of groundbreaking advancements in biotech. Her expertise ranges from novel bio-computation and biological age quantification to cutting-edge CRISPR strategies for diagnosing and treating tissue degeneration.

斯坦福大学博士研究生Conboy博士是一位着名的秘密研究人员，一直处于生物技术突破性进步的前沿。她的专业知识包括新颖的生物计算和生物年龄量化，以及用于诊断和治疗组织变性的尖端CRISPR策略。

She has received several awards from esteemed organizations including the W.M. Keck Foundation, Calico, SENS Research Foundation, and Life Extension Foundation to name a few. It’s no surprise that her numerous U.S. invention patents and impressive publications have been recognized by accredited news outlets like The Economist, Science Daily, and TIME Magazine.

她获得了一些尊敬的组织颁发的奖项，包括W.M.Keck基金会，Calico，SENS研究基金会和生命延长基金会等等。毫不奇怪，她的众多美国发明专利和令人印象深刻的出版物已被经济学人，科学每日和时间杂志等认可的新闻媒体所认可。

As a scientific advisor to Juvena Therapeutics, NovaXS biotech companies, and The Alliance for Longevity Initiative (a4li) nonprofit, Dr. Conboy is nothing short of a leader in her field..

作为Juvena Therapeutics，NovaXS biotech Companys和Alliance for Longevity Initiative（a4li）非营利组织的科学顾问，Conboy博士在该领域的领导者中无济于事。。

Dr. Conboy shared that she “was introduced to the Immunis team by Dr. Hanadie Yousef, CEO of Juvena, and one of [her] most talented former students.” She’s enthusiastic about her role as Scientific Advisor and hopes to “contribute to Immunis' quest of making enhanced healthspan a therapeutic reality through regenerative secretomes.” Undoubtedly, Dr.

Conboy博士分享说，她“由Juvena首席执行官Hanadie Yousef博士和[她]最有才能的前学生之一介绍给Immunis团队。”她对自己作为科学顾问的角色充满热情，希望“为Immunis寻求通过再生分泌蛋白组使增强健康成为治疗现实。”毫无疑问，博士。

Conboy’s unparalleled insights and innovative methodologies will guide Immunis closer to its mission of developing transformative secretome therapies..

Conboy无与伦比的见解和创新方法将指导Immunis更接近其开发变革性分泌组疗法的使命。。

About Immunis Inc.

关于Immunis Inc。

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations.

Immunis是一家私营生物技术公司，为各种年龄和疾病相关免疫衰退表现开发新型免疫调节分泌蛋白产品。研究产品系列利用Immunis在分泌组技术方面的领先能力，以天然相对生理浓度提供所有天然，全人类免疫调节剂的产品。

For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/.

有关Immunis 1/2a期临床试验的更多信息，请访问：https://immunisbiomedical.com/clinical-trials/.

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts.

本通讯包含符合1995年“私人证券诉讼改革法”（如适用）含义的构成“前瞻性陈述”的陈述。前瞻性陈述包括但不限于关于我们的计划，信念，期望和假设的陈述，以及不一定是历史事实的其他陈述。

You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication.

请注意，这些前瞻性陈述只是预测，涉及风险和不确定性。此外，任何前瞻性陈述仅在其发布之日起才发表，我们不打算更新或修改任何前瞻性陈述。本通信还包含与我们的业务和行业相关的市场数据，其中包括基于我们认为对本通信之日的预测合理且最重要的若干假设的预测。

If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein..

如果我们的任何假设被证明是不正确的，我们的实际结果可能与基于这些假设的预测显着不同。本通信既不是出售报价，也不是征求购买本文所述任何证券的报价。。